Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe.

[1]  Jean-Michel Pawlotsky,et al.  EASL Recommendations on Treatment of Hepatitis C 2018. , 2018, Journal of hepatology.

[2]  G. di Perri,et al.  Treatment with direct‐acting antiviral agents of hepatitis C virus infection in injecting drug users: A prospective study , 2017, Journal of viral hepatitis.

[3]  P. Read,et al.  Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting. , 2017, The International journal on drug policy.

[4]  C. Cunningham,et al.  High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic. , 2017, The International journal on drug policy.

[5]  S. Sockalingam,et al.  Understanding real-world adherence in the directly acting antiviral era: A prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada. , 2017, The International journal on drug policy.

[6]  C. Gilks,et al.  Initial outcomes of integrated community-based hepatitis C treatment for people who inject drugs: Findings from the Queensland Injectors' Health Network. , 2017, The International journal on drug policy.

[7]  M. Manns,et al.  Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. , 2017, The lancet. Gastroenterology & hepatology.

[8]  Joseph K. Lim,et al.  Medicaid Reimbursement for Oral Direct Antiviral Agents for the Treatment of Chronic Hepatitis C , 2017, The American Journal of Gastroenterology.

[9]  Gamal Esmat,et al.  Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. , 2017, The lancet. Gastroenterology & hepatology.

[10]  R. Chung,et al.  SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy , 2017 .

[11]  C. Cooper,et al.  Safety and efficacy of Ombitasvir, Paritaprevir/Ritonavir and Dasabuvir with or without ribavirin in chronic hepatitis C patients receiving opioid substitution therapy: a pooled analysis across 12 clinical trials , 2017 .

[12]  S. Katz,et al.  Randomized controlled trial of cash incentives or peer mentors to improve HCV linkage and treatment among HIV/HCV coinfected persons who inject drugs: the CHAMPS Study , 2017 .

[13]  N. Luhmann,et al.  Effectiveness of DAA-based treatment of HCV in active people who inject drugs living in middle income countries (MIC): the results of a prospective cohort study in Tbilisi, Georgia , 2017 .

[14]  P. Read,et al.  Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study , 2017 .

[15]  M. Ziol,et al.  Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications. , 2017, Gastroenterology.

[16]  J. Pawlotsky,et al.  EASL Recommendations on Treatment of Hepatitis C 2016. , 2017, Journal of hepatology.

[17]  A. Mangia,et al.  Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  G. Dore,et al.  Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  Lisa P. Barrett,et al.  Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study. , 2016, CMAJ open.

[20]  D. Nickle,et al.  Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. , 2016, Annals of internal medicine.

[21]  D. Vlahov,et al.  Clinicians' Views of Hepatitis C Virus Treatment Candidacy With Direct-Acting Antiviral Regimens for People Who Inject Drugs , 2016, Substance use & misuse.

[22]  M. Hellard,et al.  Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model , 2016, Gut.

[23]  Global Hepatitis Programme.  Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection. Updated version, April 2016. , 2016 .

[24]  R. Malekzadeh,et al.  Strategies to manage hepatitis C virus infection disease burden – volume 3 , 2015, Journal of viral hepatitis.

[25]  R. Malekzadeh,et al.  Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 3 , 2015, Journal of viral hepatitis.

[26]  G. Dore,et al.  Excluding people who use drugs or alcohol from access to hepatitis C treatments – Is this fair, given the available data? , 2015, Journal of hepatology.

[27]  G. Dore,et al.  Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States , 2015, Annals of Internal Medicine.

[28]  Aasld Idsa Hcv Guidance Panel.  Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus , 2015, Hepatology.

[29]  M. King,et al.  Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. , 2015, Journal of hepatology.

[30]  K. Reddy,et al.  GrazoprevirElbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection , 2015, Annals of Internal Medicine.

[31]  G. Dore,et al.  Hepatitis C virus therapeutic development: in pursuit of "perfectovir". , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  Bernadette A. Thomas,et al.  Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.

[33]  M. Leshno,et al.  Strategies to manage hepatitis C virus (HCV) infection disease burden – volume 2 , 2015, Journal of viral hepatitis.

[34]  R. Mao,et al.  Impact of nucleos(t)ide analogues on the estimated glomerular filtration rate in patients with chronic hepatitis B: a prospective cohort study in China , 2015, Journal of viral hepatitis.

[35]  M. Leshno,et al.  The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm – volume 2 , 2015, Journal of viral hepatitis.

[36]  M. Leshno,et al.  Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 2 , 2015, Journal of viral hepatitis.

[37]  J. Ward,et al.  Estimates on HCV disease burden worldwide – filling the gaps , 2015, Journal of viral hepatitis.

[38]  J. Dufour,et al.  Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. , 2014, JAMA.

[39]  G. Esmat,et al.  The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm , 2014, Journal of viral hepatitis.

[40]  Eoin Coakley,et al.  Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. , 2014, The New England journal of medicine.

[41]  M. Buti,et al.  Historical epidemiology of hepatitis C virus (HCV) in selected countries , 2014, Journal of viral hepatitis.

[42]  C. Cooper,et al.  ABT-450/r/Ombitasvir plus Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients Receiving Stable Opioid Substitution Treatment: Pooled Analysis of Efficacy and Safety in Phase 2 and Phase 3 Trials , 2014 .

[43]  G. Dore,et al.  Epidemiology and natural history of HCV infection , 2013, Nature Reviews Gastroenterology &Hepatology.

[44]  M. Hellard,et al.  Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals , 2013, Hepatology.

[45]  M. Hellard,et al.  Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[46]  G. Dore,et al.  Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels. , 2013, The Journal of infectious diseases.

[47]  G. Dore,et al.  What Is Killing People with Hepatitis C Virus Infection? , 2011, Seminars in liver disease.

[48]  Sanjeev Arora,et al.  Outcomes of treatment for hepatitis C virus infection by primary care providers. , 2011, The New England journal of medicine.

[49]  U. Siebert,et al.  HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality , 2009, BMC public health.